India-based Sun Pharmaceutical Industries Ltd has made announcement that the company along with its arm, has got first U.S. Food and Drug Administration sanction to market the generic version of a controlled substance in tablet form.

According to sources, the company is allowed to sell generic hydrocodone bitartate with acetaminophen in multiple strengths, which has a U.S. market size of $540 million for branded and generic versions.

Sun also secured approval for generic versions of cholesterol-fighting Lopid, Aredia, indicated in the treatment of high blood calcium, and anti-allergent Phenargen in multiple strengths.

Shares of the company gained Rs 0.2, or 0.02%, to settle at Rs 1,041.40. The total volume of shares traded was 46,802 at the Bombay Stock Exchange (BSE).